Equities

Immunovia AB (publ)

Immunovia AB (publ)

Actions
Health CareMedical Equipment and Services
  • Price (SEK)0.913
  • Today's Change-0.036 / -3.79%
  • Shares traded208.45k
  • 1 Year change+132.05%
  • Beta2.5530
Data delayed at least 15 minutes, as of Sep 20 2024 10:32 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Immunovia AB (publ) is a Sweden-based diagnostic company that is developing and commercializing blood tests for the early detection of cancer and autoimmune diseases based on Immunovia’s test platform called IMMray. Tests are based on antibody biomarker microarray analysis using machine-learning and bioinformatics to single-out a set of relevant biomarkers that indicate a certain disease. Thus, forming a disease biomarker signature. Immunovia Dx Laboratories locations in USA and Sweden provides laboratory testing services in two accredited reference laboratories.

  • Revenue in SEK (TTM)885.00k
  • Net income in SEK-116.12m
  • Incorporated2007
  • Employees10.00
  • Location
    Immunovia AB (publ)Medicon Village, Scheelevagen 8LUND 223 63SwedenSWE
  • Phone+46 462756000
  • Websitehttps://immunovia.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Toleranzia AB0.00-5.41m102.87m11.00--0.6808-----0.026-0.0260.000.76680.00----0.00-3.89-7.45-4.05-7.78------------0.00------11.79--63.90--
ScandiDos AB61.35m-9.67m103.19m26.00--2.36--1.68-0.2092-0.20921.270.7660.81841.316.88---12.90-12.60-23.54-21.9350.3951.58-15.76-15.370.9476-6.360.00---1.824.36-60.62---19.29--
Redsense Medical AB (publ)23.77m-3.98m108.54m5.00--3.38--4.57-0.2871-0.28711.651.950.75247.584.184,754,400.00-12.58-18.66-14.51-20.9920.47-2.72-16.72-46.284.00-89.340.00--74.1128.9448.47---23.62--
Luxbright AB4.20m-22.23m112.69m10.00--3.79--26.81-0.24-0.240.04540.26410.104--4.14420,270.00-55.02-61.39-62.23-70.36-134.43-577.85-528.90-2,529.110.7743-4,539.470.0084--55.58---20.07------
Episurf Medical AB12.10m-84.60m113.80m26.00--0.9675--9.40-0.2429-0.24290.03470.18070.0839--6.21432,142.80-58.81-47.46-67.73-52.01-----700.83-1,019.296.11--0.0321--53.6219.78-22.64---0.4158--
Glycorex Transplantation AB (publ)31.03m-27.83m119.29m15.00--3.26--3.84-0.3768-0.37680.42010.51860.4120.83823.691,348,913.00-36.96-11.30-46.32-13.1782.9191.60-89.70-33.241.09-71.860.2084---17.04-2.15-254.06---0.5593--
Iconovo AB6.10m-39.03m119.71m29.00--0.9747--19.63-3.01-3.010.45267.710.0434--1.04210,251.40-27.76-25.43-31.28-28.24323.68134.57-640.15-215.16----0.0669---58.65-9.884.71--34.70--
BibbInstruments AB0.00-11.84m128.49m4.00--3.72-----0.4417-0.44170.001.180.00-------31.46-39.57-33.52-42.71--59.36---8,032.404.34--0.00------2.72---1.94--
Phase Holographic Imaging PHI AB9.12m-21.81m146.16m17.00------16.02-0.8819-0.88190.3689-0.02730.23730.65981.18---56.73-62.04-88.25-79.6471.0663.16-239.04-328.500.1916-5.611.04--6.1617.9612.98--21.19--
Immunovia AB (publ)885.00k-116.12m171.91m10.00--4.39--194.25-1.30-1.300.00990.21620.0071--14.3980,454.55-93.50-41.33-133.56-44.24-6,702.03-7,553.76-13,120.79-20,879.29--2.480.3064--37.5536.48-84.09---50.93--
Vo2 Cap Holding AB (publ)344.05m-3.18m173.49m95.00--0.75653.910.5043-0.0594-0.05946.494.030.7088--7.973,340,253.00-0.6554-0.2564-0.8674-0.383935.8423.36-0.9246-0.2409--0.32010.1362---26.0985.65-57.92---17.96--
Neola Medical AB0.00-9.47m182.39m7.00--2.47-----0.1508-0.15080.001.050.00----0.00-12.63-17.04-13.59-18.46--4,237.20---5,258.78----0.00------12.97--55.46--
Arcoma AB175.30m12.66m200.42m31.0015.843.5510.031.140.95980.959813.304.282.023.969.195,654,936.0014.611.1224.242.0137.8537.667.220.75681.2518.830.04070.0030.366.4134.81--22.75--
Bactiquant A/S13.66m-22.02m214.37m----20.64--15.69-0.6558-0.65580.40640.29060.51012.945.06---82.23-41.26-92.65-47.16-24.3412.89-161.20-71.772.73-9.480.5326---0.689--7.62------
Nanexa AB26.91m-66.68m217.11m19.00--2.50--8.07-0.6938-0.69380.24840.64110.2108-3.832.991,416,316.00-52.24-40.77-70.59-48.77118.7777.27-247.79-532.261.92--0.0174--925.42147.00-30.44--39.10--
SpectraCure AB (publ)2.36m-21.18m220.97m13.00--1.88--93.47-0.218-0.2180.02431.210.0166--24.63157,600.00-14.82-12.75-15.91-13.62442.39195.30-895.85-494.40----0.0494---3.30--19.46------
Data as of Sep 20 2024. Currency figures normalised to Immunovia AB (publ)'s reporting currency: Swedish Krona SEK

Institutional shareholders

0.71%Per cent of shares held by top holders
HolderShares% Held
Banor Capital Ltd.as of 31 Mar 2024402.60k0.22%
SEB Investment Management ABas of 30 Aug 2024307.81k0.17%
Handelsbanken Fonder ABas of 31 Aug 2024304.61k0.17%
FCG Fonder ABas of 30 Aug 2024157.09k0.09%
Storebrand Asset Management ASas of 30 Jun 202493.60k0.05%
Skandia Investment Management ABas of 31 Jul 202424.16k0.01%
SSgA Funds Management, Inc.as of 05 Sep 2024475.000.00%
More ▼
Data from 31 Mar 2024 - 30 Aug 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.